LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
LEXICON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.55+0.03 (+1.97%)
Close on Oct 19, 2026
- Market cap
- $678.36M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
81.9%
365M of 445M shares
Institutional holders
149
45 new, 30 sold out
Net institutional buying
41M
In Q2 2026
Insider trades, 12 months
8 buys · 0 sales
Net bought $2.72M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 51,782,045 | 11.70% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson | 38,137,535 | 10.50% | 13G (passive) amendment | Jun 30, 2025 |
| Westend S.A. | 175,156,062 | 39.40% | 13D (active) amendment | Apr 30, 2026 |
| Artal International S.C.A. | 154,734,327 | 36.20% | 13D (active) amendment | Jan 29, 2026 |
| Artal Participations S.à r.l | 136,180,481 | 37.70% | 13D (active) amendment | Dec 5, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LXRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Artal Group S.A. | 175,156,062 | 39.36% | $420.37M | +20,421,735 | 45.15% |
| FMR LLC | 51,782,045 | 11.64% | $124.28M | +6,725,707 | 0.01% |
| Siren, L.L.C. | 44,303,518 | 9.96% | $106.33M | – | 2.15% |
| Sessa Capital IM, L.P. | 18,960,836 | 4.26% | $45.51M | +1,047,875 | 0.76% |
| BlackRock, Inc. | 17,348,741 | 3.90% | $41.64M | +14,026,522 | 0.00% |
| Vanguard Capital Management LLC | 9,901,208 | 2.23% | $23.76M | +382,041 | 0.00% |
| Point72 Asset Management, L.P. | 8,251,325 | 1.85% | $19.80M | +436,719 | 0.02% |
| Geode Capital Management, LLC | 6,244,372 | 1.40% | $14.99M | +3,075,261 | 0.00% |
| State Street Corp | 4,917,769 | 1.11% | $11.80M | +3,953,731 | 0.00% |
| Vanguard Portfolio Management LLC | 2,357,749 | 0.53% | $5.66M | +1,811,149 | 0.00% |
| Northern Trust Corp | 1,968,619 | 0.44% | $4.72M | +1,473,953 | 0.00% |
| Charles Schwab Investment Management Inc | 1,956,775 | 0.44% | $4.70M | +645,477 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,634,571 | 0.37% | $3.92M | +302,287 | 0.00% |
| Citadel Advisors LLC | 1,601,182 | 0.36% | $3.84M | +506,281 | 0.00% |
| Ishara Investments LP | 1,271,000 | 0.29% | $3.05M | +369,000 | 2.24% |
| Millennium Management LLC | 1,134,229 | 0.25% | $2.72M | −3,810,502 | 0.00% |
| Renaissance Technologies LLC | 1,127,000 | 0.25% | $2.70M | −473,500 | 0.00% |
| Mackenzie Financial Corp | 963,354 | 0.22% | $2.31M | +190,677 | 0.00% |
| ADAR1 Capital Management, LLC | 750,000 | 0.17% | $1.80M | – | 0.08% |
| Susquehanna International Group, Llp | 696,776 | 0.16% | $1.67M | −1,424,388 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 149 | 365M | 81.9% | 45 / 36 | 36 / 30 | 61M | 20M |
| Q1 2026 | 136 | 323M | 72.7% | 31 / 41 | 26 / 15 | 78M | 3M |
| Q4 2025 | 125 | 260M | 58.5% | 23 / 28 | 41 / 17 | 12M | 6M |
| Q3 2025 | 123 | 255M | 57.3% | 18 / 26 | 42 / 17 | 9M | 11M |
| Q2 2025 | 123 | 257M | 57.8% | 29 / 31 | 36 / 33 | 16M | 25M |
| Q1 2025 | 127 | 266M | 59.7% | 31 / 34 | 32 / 29 | 11M | 42M |
| Q4 2024 | 127 | 298M | 66.9% | 25 / 45 | 24 / 34 | 29M | 20M |
| Q3 2024 | 137 | 289M | 64.9% | 26 / 46 | 21 / 14 | 74M | 57M |
| Q2 2024 | 127 | 281M | 63.2% | 26 / 48 | 22 / 17 | 114M | 6M |
| Q1 2024 | 118 | 173M | 39.0% | 33 / 31 | 31 / 20 | 22M | 36M |
| Q4 2023 | 106 | 187M | 42.0% | 25 / 30 | 24 / 31 | 14M | 16M |
| Q3 2023 | 112 | 189M | 42.4% | 11 / 45 | 30 / 21 | 5M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LXRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 16,542,000 | 3.72% | $36.06M | 0.04% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 7,083,651 | 1.59% | $17.00M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,209,944 | 1.40% | $14.90M | 0.02% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 4,887,306 | 1.10% | $10.65M | 0.04% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 3,977,693 | 0.89% | $8.67M | 0.04% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 2,722,989 | 0.61% | $6.29M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 2,567,310 | 0.58% | $6.16M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 2,278,291 | 0.51% | $5.47M | 0.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 1,121,988 | 0.25% | $2.69M | 0.63% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,112,834 | 0.25% | $2.43M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,032,223 | 0.23% | $2.25M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 835,530 | 0.19% | $2.01M | 0.13% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 604,413 | 0.14% | $1.40M | 0.02% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 544,199 | 0.12% | $1.19M | 0.01% | May 31, 2026 |
| Select Biotechnology Portfolio | 515,300 | 0.12% | $1.12M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Exton | Chief Executive Officer, Director | 503,263 | 0.11% | Mar 3, 2026 |
| Brian T. Crum | SVP, General Counsel & Secr. | 330,201 | 0.07% | Mar 3, 2026 |
| Lisa DeFrancesco | SVP, IR and Corp Comm | 40,251 | 0.01% | Mar 3, 2026 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 67,090 | 0.02% | Mar 3, 2026 |
| Suma Gopinathan | SVP, Discovery | 88,520 | 0.02% | Mar 3, 2026 |
| Scott M. Coiante | SVP, Chief Financial Officer | 105,356 | 0.02% | Mar 3, 2026 |
| Craig B. Granowitz | SVP, Chief Medical Officer | 432,528 | 0.10% | Mar 3, 2026 |
| Wendy McDermott | SVP, Human Resources | 277,945 | 0.06% | Mar 3, 2026 |
| Kristen Alexander | VP, Finance and Accounting | 76,368 | 0.02% | Mar 3, 2025 |
| Alan J. Main | EVP, Innov & Chem Sciences | 281,391 | 0.06% | Mar 3, 2025 |
| Brian Corrigan | SVP, Regulatory & QA | – | – | Feb 18, 2025 |
| Diane E. Sullivan | Director | 126,122 | 0.03% | Jun 4, 2026 |
| Judith L. Swain | Director | 174,486 | 0.04% | Jun 4, 2026 |
| Ivan Cheung | Director | 89,312 | 0.02% | Jun 4, 2026 |
| Sam L. Barker | Director | 248,771 | 0.06% | Jun 4, 2026 |
| Raymond Debbane | Director | 51,750,221 | 11.63% | Jun 4, 2026 |
| Philippe Amouyal | Director | 374,486 | 0.08% | Jun 4, 2026 |
| Christopher J. Sobecki | Director | 293,177 | 0.07% | Jun 4, 2026 |
| S.A. Westend | Director, 10% owner | 3,333,376 | 0.75% | May 8, 2026 |
| Administratiekantoor Westend Stichting | Director, 10% owner | 1,150,922 | 0.26% | May 8, 2026 |
| International Management S.A. Artal | Director, 10% owner | 3,006,678 | 0.68% | May 8, 2026 |
| International S.C.A. Artal | Director, 10% owner | 408,435 | 0.09% | May 8, 2026 |
| Group S.A. Artal | Director, 10% owner | 367,145 | 0.08% | May 8, 2026 |
| Amaury Wittouck | Director, 10% owner | 3,516,214 | 0.79% | May 8, 2026 |
| Participations S.a r.l. Artal | Director, 10% owner | 311,336,543 | 69.97% | May 8, 2026 |
| Life Sci Master GP LLC Avicenna | Director, 10% owner | 1,538,462 | 0.35% | Feb 12, 2026 |
| Life Sci Master Fund LP Avicenna | Director, 10% owner | – | – | Feb 12, 2026 |
| Invus Global Management, LLC | Director, 10% owner | – | – | Feb 4, 2026 |
| Siren, L.L.C. | Director, 10% owner | 35,402,689 | 7.96% | Feb 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Diane E. Sullivan Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 126,122 |
| Ivan Cheung Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 89,312 |
| Raymond Debbane Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 1,995,498 |
| Sam L. Barker Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 213,771 |
| Judith L. Swain Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 174,486 |
| Christopher J. Sobecki Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 293,177 |
| Philippe Amouyal Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 374,486 |
| Participations S.a r.l. Artal Director, 10% owner | Apr 30, 2026 | Option exercise | +20,421,735 | – | – | 175,156,062 |
| Suma Gopinathan SVP, Discovery | Feb 28, 2026 | Option exercise | +14,000 | – | – | 88,520 |
| Suma Gopinathan SVP, Discovery | Feb 28, 2026 | Option exercise | +20,310 | – | – | 108,830 |
| Suma Gopinathan SVP, Discovery | Feb 28, 2026 | Tax withholding | −24,338 | $1.47 | $35.78K | 150,132 |
| Suma Gopinathan SVP, Discovery | Feb 28, 2026 | Option exercise | +65,640 | – | – | 174,470 |
| Scott M. Coiante SVP, Chief Financial Officer | Feb 28, 2026 | Tax withholding | −54,881 | $1.47 | $80.68K | 105,356 |
| Scott M. Coiante SVP, Chief Financial Officer | Feb 28, 2026 | Option exercise | +160,237 | – | – | 160,237 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2026 | Option exercise | +24,674 | – | – | 40,251 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2026 | Option exercise | +128,190 | – | – | 168,441 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2026 | Tax withholding | −74,572 | $1.47 | $109.62K | 93,869 |
| Rachel Yap Martens SVP, Partnerships & Corp Strat | Feb 28, 2026 | Option exercise | +67,090 | – | – | 67,090 |
| Rachel Yap Martens SVP, Partnerships & Corp Strat | Feb 28, 2026 | Tax withholding | −35,826 | $1.47 | $52.66K | 31,264 |
| Michael Exton Chief Executive Officer, Director | Feb 28, 2026 | Option exercise | +503,263 | – | – | 503,263 |
| Michael Exton Chief Executive Officer, Director | Feb 28, 2026 | Tax withholding | −204,831 | $1.47 | $301.10K | 298,432 |
| Wendy McDermott SVP, Human Resources | Feb 28, 2026 | Tax withholding | −68,107 | $1.47 | $100.12K | 277,945 |
| Wendy McDermott SVP, Human Resources | Feb 28, 2026 | Option exercise | +144,393 | – | – | 346,052 |
| Wendy McDermott SVP, Human Resources | Feb 28, 2026 | Option exercise | +27,697 | – | – | 149,343 |
| Wendy McDermott SVP, Human Resources | Feb 28, 2026 | Option exercise | +52,316 | – | – | 201,659 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2026 | Option exercise | +69,386 | – | – | 330,201 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2026 | Tax withholding | −105,019 | $1.47 | $154.38K | 428,802 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2026 | Option exercise | +33,457 | – | – | 363,658 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2026 | Option exercise | +170,163 | – | – | 533,821 |
| Craig B. Granowitz SVP, Chief Medical Officer | Feb 28, 2026 | Option exercise | +202,260 | – | – | 432,528 |
| Craig B. Granowitz SVP, Chief Medical Officer | Feb 28, 2026 | Tax withholding | −109,098 | $1.47 | $160.37K | 323,430 |
| Craig B. Granowitz SVP, Chief Medical Officer | Feb 28, 2026 | Option exercise | +74,226 | – | – | 230,268 |
| Craig B. Granowitz SVP, Chief Medical Officer | Feb 28, 2026 | Option exercise | +35,790 | – | – | 156,042 |
| Raymond Debbane Director | Feb 25, 2026 | Buy | +2,000 | $1.49 | $2.98K | 1,906,186 |
| Raymond Debbane Director | Feb 23, 2026 | Buy | +100,000 | $1.47 | $147.00K | 1,904,186 |
| Raymond Debbane Director | Feb 20, 2026 | Buy | +100,000 | $1.48 | $148.00K | 1,804,186 |
| Raymond Debbane Director | Feb 19, 2026 | Buy | +50,000 | $1.44 | $72.00K | 1,704,186 |
| Raymond Debbane Director | Feb 18, 2026 | Buy | +133,688 | $1.32 | $176.47K | 1,654,186 |
| International S.C.A. Artal Director, 10% owner | Feb 17, 2026 | Award | +41,289.58 | $65.00 | $2.68M | 408,435 |
| Raymond Debbane Director | Feb 17, 2026 | Buy | +76,857 | $1.31 | $100.68K | 1,520,498 |
| Raymond Debbane Director | Feb 13, 2026 | Buy | +57,952 | $1.31 | $75.92K | 1,443,641 |
| Group S.A. Artal Director, 10% owner | Feb 2, 2026 | Award | +367,145.12 | $65.00 | $23.86M | 367,145 |
| Group S.A. Artal Director, 10% owner | Feb 2, 2026 | Award | +18,553,846 | $1.30 | $24.12M | 154,734,327 |
| Group S.A. Artal Director, 10% owner | Feb 2, 2026 | Award | +3,846,154 | $1.30 | $5.00M | 7,362,368 |
| Group S.A. Artal Director, 10% owner | Feb 2, 2026 | Buy | +1,538,462 | $1.30 | $2.00M | 1,538,462 |
| Christopher J. Sobecki Director | May 13, 2025 | Option exercise | +36,810 | – | – | 203,865 |
| Sam L. Barker Director | May 13, 2025 | Option exercise | +36,810 | – | – | 124,459 |
| Judith L. Swain Director | May 13, 2025 | Option exercise | +36,810 | – | – | 85,174 |
| Diane E. Sullivan Director | May 13, 2025 | Option exercise | +36,810 | – | – | 36,810 |
| Philippe Amouyal Director | May 13, 2025 | Option exercise | +36,810 | – | – | 285,174 |
| Raymond Debbane Director | May 13, 2025 | Option exercise | +36,810 | – | – | 1,385,689 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2025 | Tax withholding | −45,622 | $0.67 | $30.57K | 260,815 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2025 | Option exercise | +69,387 | – | – | 306,437 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2025 | Option exercise | +33,456 | – | – | 237,050 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2025 | Option exercise | +26,097 | – | – | 203,594 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2025 | Option exercise | +24,673 | – | – | 24,673 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2025 | Tax withholding | −9,096 | $0.67 | $6.09K | 15,577 |
| Alan J. Main EVP, Innov & Chem Sciences | Feb 28, 2025 | Option exercise | +25,667 | – | – | 281,391 |
| Alan J. Main EVP, Innov & Chem Sciences | Feb 28, 2025 | Option exercise | +32,904 | – | – | 314,295 |
| Alan J. Main EVP, Innov & Chem Sciences | Feb 28, 2025 | Option exercise | +68,243 | – | – | 382,538 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lonnel Coats Former Affiliate | Aug 15, 2024 | 300,000 | $480.00K | Aug 15, 2024 | Restricted Stock Lapse - see remarks |
| Kiernan Seth Former Affiliate | Jul 12, 2023 | 19,000 | $43.89K | Jul 12, 2023 | Restricted Stock Lapse |